Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm?

Wu, Lihteh; Acón, Dhariana; Wu, Andrés; Wu, Max

Wu, Lihteh; Acón, Dhariana; Wu, Andrés; Wu, Max.

Afiliación

Wu L; Macula, Vitreous and Retina Associates of Costa Rica, San José, Costa Rica, USA.
Acón D; Illinois Eye and Ear Infirmary, University of Illinois, Chicago, Illinois, USA.
Wu A; Department of Ophthalmology, Bascom Palmer Eye Insitute, Miami, FL, USA.
Wu M; Macula, Vitreous and Retina Associates of Costa Rica, San José, Costa Rica, USA.

Taiwan J Ophthalmol ; 9(4): 216-223, 2019.

Article en En | MEDLINE | ID: mdl-31942426

Palabras clave

Aflibercept; bevacizumab; diabetic retinopathy severity scale; intravitreal injection; panretinal photocoagulation; pattern scanning laser photocoagulation; proliferative diabetic retinopathy; ranibizumab; vascular endothelial growth factor

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Taiwan J Ophthalmol Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google